Mustang Bio (DB:2W60) - Aandelenkoers, Nieuws & Analyse

2W60 Overzicht aandelen

A clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Meer informatie

2W60 fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	5/6
Dividenden	0/6

Risicoanalyse

De winst zal naar verwachting de komende drie jaar met gemiddeld 2.4% per jaar dalen.

Heeft een omzet van minder dan 1 miljoen USD ( $0 )

Aandelen zijn zeer illiquide

Heeft geen betekenisvolle marktkapitalisatie ( €50M )

+ 2 meer risico's

Mustang Bio, Inc. Concurrenten

4SC

DB:VSC

€50.2m

2invest

XTRA:2INV

€62.7m

Medigene

XTRA:MDG1

€17.4m

Heidelberg Pharma

XTRA:HPHA

€105.8m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor Mustang Bio
Historische aandelenkoersen
Huidige aandelenkoers	US$4.84
52 Week Hoogtepunt	US$11.06
52 Week Laag	US$4.19
Bèta	1.85
11 maand verandering	0%
3 maanden verandering	-3.53%
1 Jaar Verandering	-40.63%
33 jaar verandering	n/a
5 jaar verandering	n/a
Verandering sinds IPO	-88.23%

Recent nieuws en updates

Recent updates

Rendement voor aandeelhouders

	2W60	DE Biotechs	DE Markt
7D	0%	-1.1%	1.1%
1Y	-40.6%	-18.8%	7.2%

Rendement versus industrie: 2W60 presteerde slechter dan de German Biotechs -sector, die het afgelopen jaar een rendement van -18.8 % opleverde.

Rendement versus markt: 2W60 presteerde slechter dan German Market, dat het afgelopen jaar een rendement van 7.2 % opleverde.

Prijsvolatiliteit

Is 2W60's price volatile compared to industry and market?
2W60 volatility
2W60 Average Weekly Movement	n/a
Biotechs Industry Average Movement	6.6%
Market Average Movement	4.8%
10% most volatile stocks in DE Market	10.9%
10% least volatile stocks in DE Market	2.4%

Stabiele aandelenkoers: 2W60 heeft de afgelopen 3 maanden geen significante prijsvolatiliteit gekend.

Volatiliteit in de loop van de tijd: Onvoldoende gegevens om de volatiliteitsverandering van 2W60 in het afgelopen jaar te bepalen.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
2015	113	Manny Litchman	www.mustangbio.com

Mustang Bio, Inc. Samenvatting

Hoe verhouden de winst en inkomsten van Mustang Bio zich tot de beurswaarde?
2W60 fundamentele statistieken
Marktkapitalisatie	€46.25m
Inkomsten(TTM)	-€68.20m
Inkomsten(TTM)	n/a

0.0x

P/S-verhouding

-0.7x

Koers/Winstverhouding

Is 2W60 overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
2W60 resultatenrekening (TTM)
Inkomsten	US$0
Kosten van inkomsten	US$0
Brutowinst	US$0
Overige uitgaven	US$74.42m
Inkomsten	-US$74.42m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-9.16
Brutomarge	0.00%
Nettowinstmarge	0.00%
Schuld/Eigen Vermogen Verhouding	92.5%

Hoe presteerde 2W60 op de lange termijn?

Bekijk historische prestaties en vergelijking

2W60 Overzicht aandelen

Risicoanalyse

Mustang Bio, Inc. Concurrenten

DB:VSC

€50.2m

XTRA:2INV

€62.7m

XTRA:MDG1

€17.4m

XTRA:HPHA

€105.8m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Recent updates

Nasdaq Hearings Panel Grants Mustang Bio's Request for an Extension Through January 31, 2025, to Demonstrate Compliance with the Bid Price Rule, and Through February 18, 2025, to Demonstrate Compliance with the Equity Rule

Listing Qualifications Department of Nasdaq Determines to Delist the Mustang Bio's Securities from Nasdaq

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $2.51299 million.

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $5.6 million.

Mustang Bio, Inc. Announces Favorable Efficacy and Safety Data from Complete Waldenstrom Macroglobulinemia Cohort of Phase 1/2 Clinical Trial of Mb-106, Cd20-Targeted Autologous Car-T Therapy

Mustang Bio Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Bid Price Requirement Under Nasdaq Listing Rule 5550(a)(2) for Continued Listing on the Nasdaq Capital Market

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $3.998428 million.

Mustang Bio, Inc Announces Vision for CAR T-Cell Therapy Platform Expansion into Autoimmune Diseases

Mustang Bio Receives Deficiency Letter from Nasdaq Due to Non-Compliance with the Minimum Stockholders’ Equity Requirement Under Nasdaq Listing Rule 5550(b)(1)

Mustang Bio, Inc. has filed a Follow-on Equity Offering in the amount of $10.5 million.

Mustang Bio, Inc. Announces Publication in Nature Medicine of Data from Phase 1 Trial Evaluating MB-101IL13Ra2-targeted CAR T-Cells in High-Grade Glioma

Mustang Bio, Inc. Appoints Peter Carney as the Interim Chief Accounting Officer

Mustang Bio, Inc. announced that it has received $4.742942 million in funding

Mustang Bio, Inc. has completed a Follow-on Equity Offering in the amount of $4.398333 million.

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-109, A Novel Combination of MB-101 (IL13RA2-Targeted Car-T Cell Therapy) and MB-108 (HSV-1 Oncolytic Virus), for the Treatment of Recurrent Glioblastoma and High-Grade Astrocytoma

Mustang Bio, Inc. Announces First Data from Ongoing Multicenter Phase 1/2 Clinical Trial Evaluating MB-106 CAR-T Cell Therapy

uBriGene (Boston) Biosciences Inc. completed the acquisition of Worcester manufacturing facility of Mustang Bio, Inc.

Mustang Bio Announces Final Results from Follicular Lymphoma Cohort of Single-Institution Phase 1/2 Clinical Trial of MB-106, CD20-Targeted Autologous CAR T Therapy

uBriGene (Boston) Biosciences Inc. entered into asset purchase agreement to acquire Worcester manufacturing facility of Mustang Bio, Inc. for $11 million.

Mustang Bio, Inc. Provides CAR T Cell Therapy Portfolio Updates and 2023 Anticipated Milestones

Insufficient new directors

Mustang Bio Announces First Patient Treated in Its Multicenter Phase 1/2 Clinical Trial of Mb-106, A First-In-Class Cd20-Targeted, Autologous Car T Cell Therapy to Treat B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio Announces First Patient Successfully Treated by Ex Vivo Lentiviral Gene Therapy to Treat Rag1 Severe Combined Immunodeficiency

Mustang Bio, Inc. Announces Updated Interim Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy

Mustang Bio Receives Letter from the Listing Qualifications Staff of Nasdaq

Mustang Bio, Inc. Announces Updated Interim Data on X-Linked Severe Combined Immunodeficiency Treatment with Lentiviral Vector Gene Therapy Support Upcoming Multicenter Pivotal Phase 2 Trial for MB-107

Mustang Bio, Inc. Announces Results from Follicular Lymphoma Cohort of Ongoing Phase 1/2 Clinical Trial of MB-106, CD20-Targeted CAR T Therapy, Selected for Oral Presentation at European Hematology Association 2022 Hybrid Congress

Mustang Bio, Inc. Announces Data on Treatment with Lentiviral Viral Vector Gene Therapy for X-Linked Severe Combined Immunodeficiency Selected for Oral Presentation at American Society of Gene & Cell Therapy 25th Annual Meeting

Mustang Bio, Inc., Annual General Meeting, Jun 21, 2022

Insufficient new directors

Mustang Bio Inc. Announces Updated Interim Phase 1/2 Data for Mb-106, Cd20-Targeted Car T Therapy, in Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia

Mustang Bio, Inc. Appoints Eliot M. Lurier as Interim Chief Financial Officer

Mustang Bio, Inc. Announces Phase 1 Clinical Trial Combining MB-101 and MB-108 for the Treatment of Glioblastoma

Mustang Bio Provides an Update on its IND Application for MB-207, a Lentiviral Gene Therapy for Treatment of X-linked Severe Combined Immunodeficiency in Previously Transplanted Patients

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at the 2022 Tandem Meetings I Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR

Mustang Bio Announces MB-101 (IL13Ra2-targeted CAR T cells) Scientific Presentations at Upcoming Virtual Conferences

President recently bought €211k worth of stock

Mustang Bio, Inc. Receives European Medicines Agency PRIME Designation for MB-107 to Treat X-Linked Severe Combined Immunodeficiency in Newly Diagnosed Infants

Mustang Bio, Inc.(NasdaqGM:MBIO) dropped from Russell 2500 Growth Index

Mustang Bio Announces Updated Interim Phase 1/2 Data for MB-106 CD20-Targeted CAR T in Patients with Relapsed or Refractory B-cell Non-Hodgkin Lymphomas and Chronic Lymphocytic Leukemia

Mustang Bio and City of Hope Announce First Patient Dosed in Phase 1 Clinical Trial of MB-101 to Treat Leptomeningeal Brain Tumors

Mustang Bio Announces MB-106 CD20-Targeted CAR T Data Selected for Presentation at European Hematology Association 2021 Virtual Congress

Mustang Bio, Inc. Announces FDA Acceptance of IND Application for MB-106, a CD20-Targeted CAR T Therapy

Key Executive recently sold €56k worth of stock